Clinical Trial Update: A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and efficacy of Synvisc (hylan G-F 20) for symptomatic osteoarthritis of the knee has completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Synvisc (Hylan G-F 20)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Osteoarthritis, Knee, Musculoskeletal Diseases | Phase 3 | Status: COMPLETED | Results posted: 2012-01-19